A Framework of Care in Multiple Sclerosis, Part 1.

Autor: Newsome, Scott D., Aliotta, Philip J., Bainbridge, Jacquelyn, Bennett, Susan E., Cutter, Gary, Fenton, Kaylan, Lublin, Fred, Northrop, Dorothy, Rintell, David, Walker, Bryan D., Weigel, Megan, Zackowski, Kathleen, Jones, David E.
Předmět:
Zdroj: International Journal of MS Care; Nov/Dec2016, Vol. 18 Issue 6, p314-323, 10p
Abstrakt: The Consortium of Multiple Sclerosis Centers brought together a multidisciplinary group of clinicians and researchers to explore and evaluate current standards in multiple sclerosis (MS) care. This Framework Taskforce comprised 13 clinician-experts from varying fields, including neurology, biostatistics, MS nursing, pharmacy, physician assistants, rehabilitation specialists, psychology, social work, and urology. The methods of this initiative included analysis of a needs assessment survey and an extensive literature review. The outcome is a two-part continuing education series reviewing best practices on specific key topics in MS care. Part 1, presented herein, discusses the background of MS care and focuses on the disease-modifying therapies (DMTs) currently approved by the US Food and Drug Administration for use in MS. Best practices emphasize a comprehensive, multidisciplinary, patient-centered team approach. Included are suggestions for effective communication among health-care team members. Up-to-date information is provided on the clinical course of MS, including current disease-specific terminology, which is of utmost importance in identifying optimal treatments for people with MS. Specific circumstances that health-care providers may encounter are presented, including methods for selecting a DMT, when to switch therapies, and treatment and evaluation considerations when a suboptimal response to therapy occurs. In addition, standardized magnetic resonance imaging is important for diagnosis and follow-up. Magnetic resonance imaging is recommended before starting medication therapy or switching DMTs; new lesions suggest the need to confirm adherence or consider advancing therapy. Shared decision making among health-care providers and people with MS is encouraged. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index